Page 1 of 14Free preview · 1–5

About this document

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENGERIX-B safely and effectively. See full prescribing information for ENGERIX-B. ENGERIX-B [Hepatitis B Vaccine (Recombinant)] injectable suspension, for intramuscular use Initial U.S. Approval: 1989 ----------------------------- INDICATIONS AND USAGE---------------------------- ENGERIX-B is a vaccine indicated for immunization against infection caused by all known subtypes of hepatitis B virus.

Free preview text

The first 5 pages, shown as text so search engines and readers can find this document.

Page 1

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENGERIX-B safely and effectively. See full prescribing information for ENGERIX-B. ENGERIX-B [Hepatitis B Vaccine (Recombinant)] injectable suspension, for intramuscular use Initial U.S. Approval: 1989 ----------------------------- INDICATIONS AND USAGE---------------------------- ENGERIX-B is a vaccine indicated for immunization against infection caused by all known subtypes of hepatitis B virus. (1) ------------------------- DOSAGE AND ADMINISTRATION ----------------------- For intramuscular use. (2.2) • Persons from birth through 19 years of age: A series of 3 doses (0.5 mL each) on a 0-, 1-, 6-month schedule. (2.3) • Persons 20 years of age and older: A series of 3 doses (1 mL each) on a 0-, 1-, 6-month schedule. (2.3) • Adults on hemodialysis: A series of 4 doses (2 mL each) as a single 2 mL dose or as two 1 mL doses on a 0-, 1-, 2-, 6-month schedule. (2.3) --------------------- DOSAGE FORMS AND STRENGTHS---------------------- Injectable suspension available in the following presentations: • 0.5 mL (10 mcg) prefilled syringes (3) • 1 mL (20 mcg) single dose vials and prefilled syringes (3) -------------------------------- CONTRAINDICATIONS ------------------------------ Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B-containing vaccine, or to any component of ENGERIX-B, including yeast. (4) ------------------------ WARNINGS AND PRECAUTIONS ----------------------- • Syncope (fainting) can occur in association with administration of injectable vaccines, including ENGERIX-B. Procedures should be in place to avoid injury from fainting. (5.1) • Temporarily defer vaccination of infants with a birth weight less than 2,000 g born to hepatitis B surface antigen (HBsAg)-negative mothers. (5.2) • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Decisions about when to administer an intramuscular vaccine, including ENGERIX-B, to infants born prematurely should be based on consideration of the infant’s medical status, and the potential benefits and possible risks of vaccination. (5.3) ------------------------------- ADVERSE REACTIONS ------------------------------ The most common solicited adverse reactions were injection-site soreness (22%) and fatigue (14%). (6.1) To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov. ------------------------ USE IN SPECIFIC POPULATIONS ----------------------- Antibody responses are lower in persons older than 60 years than in younger adults. (8.5) See 17 for PATIENT COUNSELING INFORMATION. Revised: 5/2026 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Preparation for Administration 2.2 Administration 2.3 Recommended Dose and Schedule 2.4 Alternate Dosing Schedules 2.5 Booster Vaccinations 2.6 Known or Presumed Exposure to Hepatitis B Virus 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Syncope 5.2 Infants Weighing Less than 2,000 g at Birth 5.3 Apnea in Premature Infants 5.4 Preventing and Managing Allergic Reactions 5.5 Moderate or Severe Acute Illness 5.6 Altered Immunocompetence 5.7 Multiple Sclerosis 5.8 Limitations of Vaccine Effectiveness 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Interference with Laboratory Tests 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Efficacy in Neonates 14.2 Efficacy and Immunogenicity in Specific Populations 14.3 Immunogenicity in Neonates 14.4 Immunogenicity in Children and Adults 14.5 Interchangeability with Other Hepatitis B Vaccines 15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed. FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. 2 DOSAGE AND ADMINISTRATION For intramuscular use. See Section 2.2 for subcutaneous use in persons at risk of hemorrhage.

Page 2

2 2.1 Preparation for Administration Shake well before use. With thorough agitation, ENGERIX-B is a homogeneous, turbid white suspension. Do not administer if it appears otherwise. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered. 2.2 Administration Administer ENGERIX-B intramuscularly. ENGERIX-B should not be administered in the gluteal region; such injections may result in suboptimal response. ENGERIX-B may be administered subcutaneously to persons at risk of hemorrhage (e.g., hemophiliacs). However, hepatitis B vaccines administered subcutaneously are known to result in a lower antibody response. Additionally, when other aluminum-adsorbed vaccines have been administered subcutaneously, an increased incidence of local reactions including subcutaneous nodules has been observed. Therefore, subcutaneous administration should be used only in persons who are at risk of hemorrhage with intramuscular injections. 2.3 Recommended Dose and Schedule Persons from Birth through 19 Years Primary immunization for infants (born of hepatitis B surface antigen [HBsAg]-negative or HBsAg-positive mothers), children (birth through 10 years), and adolescents (aged 11 through 19 years) consists of a series of 3 doses (0.5 mL each) given on a 0-, 1-, and 6-month schedule. Persons Aged 20 Years and Older Primary immunization for persons aged 20 years and older consists of a series of 3 doses (1 mL each) given on a 0-, 1-, and 6-month schedule. Adults on Hemodialysis Primary immunization consists of a series of 4 doses (2 mL each) given as a single 2 mL dose or two 1 mL doses on a 0-, 1-, 2-, and 6-month schedule. In hemodialysis patients, antibody response is lower than in healthy persons and protection may persist only as long as antibody levels remain above 10 mIU/mL. Therefore, the need for booster doses should be assessed by annual antibody testing. A 2 mL booster dose (as a single 2 mL dose or two 1 mL doses) should be given when antibody levels decline below 10 mIU/mL1 [see Clinical Studies (14.2)].

Page 3

3 Table 1. Recommended Dosage and Administration Schedules Group Dosea Schedules Infants born of: HBsAg-negative mothers 0.5 mL 0, 1, 6 months HBsAg-positive mothersb 0.5 mL 0, 1, 6 months Children: Birth through 10 years 0.5 mL 0, 1, 6 months Adolescents: Aged 11 through 19 years 0.5 mL 0, 1, 6 months Adults: Aged 20 years and older 1 mL 0, 1, 6 months Adults on hemodialysis 2 mLc 0, 1, 2, 6 months HBsAg = Hepatitis B surface antigen. a 0.5 mL (10 mcg); 1 mL (20 mcg). b Infants born to HBsAg-positive mothers should receive vaccine and hepatitis B immune globulin (HBIG) within 12 hours after birth [see Dosage and Administration (2.6)]. c Given as a single 2 mL dose or as two 1 mL doses. 2.4 Alternate Dosing Schedules There are alternate dosing and administration schedules which may be used for specific populations (e.g., neonates born of hepatitis B–infected mothers, persons who have or might have been recently exposed to the virus, and travelers to high-risk areas) (Table 2). For some of these alternate schedules, an additional dose at 12 months is recommended for prolonged maintenance of protective titers. Table 2. Alternate Dosage and Administration Schedules Group Dosea Schedules Infants born of: HBsAg-positive mothersb 0.5 mL 0, 1, 2, 12 months Children: Birth through 10 years 0.5 mL 0, 1, 2, 12 months Aged 5 through 10 years 0.5 mL 0, 12, 24 monthsc Adolescents: Aged 11 through 16 years 0.5 mL 0, 12, 24 monthsc Aged 11 through 19 years 1 mL 0, 1, 6 months Aged 11 through 19 years 1 mL 0, 1, 2, 12 months Adults: Aged 20 years and older 1 mL 0, 1, 2, 12 months HBsAg = Hepatitis B surface antigen. a 0.5 mL (10 mcg); 1 mL (20 mcg). b Infants born to HBsAg-positive mothers should receive vaccine and hepatitis B immune globulin (HBIG) within 12 hours after birth [see Dosage and Administration (2.6)]. c For children and adolescents for whom an extended administration schedule is acceptable based on risk of exposure.

Page 4

4 2.5 Booster Vaccinations Whenever administration of a booster dose is appropriate, the dose of ENGERIX-B is 0.5 mL for children aged 10 years and younger and 1 mL for persons aged 11 years and older. Studies have demonstrated a substantial increase in antibody titers after booster vaccination with ENGERIX-B. See Section 2.3 for information on booster vaccination for adults on hemodialysis. 2.6 Known or Presumed Exposure to Hepatitis B Virus Persons with known or presumed exposure to the hepatitis B virus (e.g., neonates born of infected mothers, persons who experienced percutaneous or permucosal exposure to the virus) should be given hepatitis B immune globulin (HBIG) in addition to ENGERIX-B in accordance with Advisory Committee on Immunization Practices recommendations and with the package insert for HBIG. ENGERIX-B may be administered concomitantly with immune globulin with different syringes and at different administration sites. ENGERIX-B can be given on either dosing schedule (0, 1, and 6 months or 0, 1, 2, and 12 months). 3 DOSAGE FORMS AND STRENGTHS ENGERIX-B is a sterile injectable suspension available in the following presentations: • 0.5 mL (10 mcg) prefilled TIP-LOK syringes • 1 mL (20 mcg) single-dose vials and prefilled TIP-LOK syringes [see Description (11), How Supplied/Storage and Handling (16)] [For dose information, see Dosage and Administration (2.3, 2.4, 2.5)] 4 CONTRAINDICATIONS Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B-containing vaccine, or to any component of ENGERIX-B, including yeast, is a contraindication to administration of ENGERIX-B [see Description (11)]. 5 WARNINGS AND PRECAUTIONS 5.1 Syncope Syncope (fainting) can occur in association with administration of injectable vaccines, including ENGERIX-B. Procedures should be in place to avoid injury from fainting. 5.2 Infants Weighing Less than 2,000 g at Birth Hepatitis B vaccine should be deferred for infants with a birth weight <2,000 g if the mother is documented to be HBsAg negative at the time of the infant’s birth. Vaccination can commence at chronological age 1 month or hospital discharge. Infants born weighing <2,000 g to HBsAg-positive mothers should receive vaccine and HBIG within 12 hours after birth. Infants born weighing <2,000 g to mothers of unknown HBsAg status should receive vaccine and HBIG within 12 hours after birth if the mother’s HBsAg status cannot be determined within the first 12 hours of life. The birth dose in infants born weighing <2,000 g should not be counted as the first dose in the vaccine series and it should be followed with a full 3-dose standard regimen (total of 4 doses)2 [see Dosage and Administration (2)].

Page 5

5 5.3 Apnea in Premature Infants Apnea following intramuscular vaccination has been observed in some infants born prematurely. Decisions about when to administer an intramuscular vaccine, including ENGERIX-B, to infants born prematurely should be based on consideration of the infant’s medical status, and the potential benefits and possible risks of vaccination. For ENGERIX-B, this assessment should include consideration of the mother’s hepatitis B antigen status and the high probability of maternal transmission of hepatitis B virus to infants born of mothers who are HBsAg positive if vaccination is delayed. 5.4 Preventing and Managing Allergic Reactions Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of ENGERIX-B. 5.5 Moderate or Severe Acute Illness To avoid diagnostic confusion between manifestations of an acute illness and possible vaccine adverse effects, vaccination with ENGERIX-B should be postponed in persons with moderate or severe acute febrile illness unless they are at immediate risk of hepatitis B infection (e.g., infants born of HBsAg-positive mothers). 5.6 Altered Immunocompetence Immunocompromised persons may have a diminished immune response to ENGERIX-B, including individuals receiving immunosuppressant therapy. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater-than-physiologic doses), may reduce the immune response to ENGERIX-B. 5.7 Multiple Sclerosis Results from 2 clinical studies indicate that there is no association between hepatitis B vaccination and the development of multiple sclerosis,3 and that vaccination with hepatitis B vaccine does not appear to increase the short-term risk of relapse in multiple sclerosis.4 5.8 Limitations of Vaccine Effectiveness Hepatitis B has a long incubation period. ENGERIX-B may not prevent hepatitis B infection in individuals who had an unrecognized hepatitis B infection at the time of vaccine administration. Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers. 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. In 36 clinical studies, a total of 13,495 doses of ENGERIX-B were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers, and healthy neonates. All participants were monitored for 4 days post-administration. Frequency of adverse reactions tended to decrease with successive doses of ENGERIX-B.

Doxxly editorial guide

1 FULL PRESCRIBING INFORMATION 1 INDICATIONS ...: summary, contents and background

This guide helps you understand the scope of 1 FULL PRESCRIBING INFORMATION 1 INDICATIONS ... before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.

Summary and overview

1 FULL PRESCRIBING INFORMATION 1 INDICATIONS ... is a 14-page documentcredited to Soren F. Bellweather. 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENGERIX-B safely and effectively. See full prescribing information for ENGERIX-B. ENGERIX-B [Hepatitis B Vaccine (Recombinant)] injectable suspension, for intramuscular use Initial U.S. Approval: 1989 ----------------------------- INDICATIONS AND USAGE---------------------------- ENGERIX-B is a vaccine indicated for immunization against infection caused by all known subtypes of hepatitis B virus.

The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of its central subject with the related resources linked below.

Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.

Key topics and reader takeaways

The catalogue connects this document with its central subject. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.

A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.

Table of contents and reading guide

The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 14 pages in the player.

  1. Part 1

    background

    Use this section of the reading guide to identify how background appears in 1 FULL PRESCRIBING INFORMATION 1 INDICATIONS ..., note important terms, and connect the subject to the wider purpose of the work.

  2. Part 2

    key ideas

    Use this section of the reading guide to identify how key ideas appears in 1 FULL PRESCRIBING INFORMATION 1 INDICATIONS ..., note important terms, and connect the subject to the wider purpose of the work.

  3. Part 3

    practical context

    Use this section of the reading guide to identify how practical context appears in 1 FULL PRESCRIBING INFORMATION 1 INDICATIONS ..., note important terms, and connect the subject to the wider purpose of the work.

When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.

About Soren F. Bellweather

Doxxly credits Soren F. Bellweather as the author or creator of 1 FULL PRESCRIBING INFORMATION 1 INDICATIONS .... This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.

Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.

About the source organisation

The recorded source for this item is gskpro.com. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.

Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.

Visit gskpro.com

How to read and use this document

Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.

The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.

If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.

Research questions to consider

As you read 1 FULL PRESCRIBING INFORMATION 1 INDICATIONS ..., ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.

A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the related collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.

Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.

Frequently asked questions about 1 FULL PRESCRIBING INFORMATION 1 INDICATIONS ...

Practical answers about reading, downloading and understanding this document on Doxxly.